» Articles » PMID: 31362295

Loop Diuretics in Acute Kidney Injury Prevention, Therapy, and Risk Stratification

Overview
Publisher Karger
Specialty Nephrology
Date 2019 Jul 31
PMID 31362295
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Loop diuretics (LD) are widely used in emergency and intensive care medicine.

Summary: The substances increase the clearance of electrolytes and water; thus, they allow us to control hypervolemia and to prevent patients from pulmonary edema. LD are also frequently applied to patients with an acute decrease in glomerular filtration rate, namely, acute kidney injury (AKI). Nevertheless, volume depletion may be associated with reduced renal perfusion and possibly slower restitution or even aggravation of kidney dysfunction. Several trials on the preventive or therapeutic efficacy of LD have been published since the early 1970s. Our review article is intended to summarize the most important references related to this topic. In addition, we discuss the diagnostic value of the so-called furosemide stress test. The currently available data indicate that LD may act in a beneficial manner as long as euvolemia is maintained (matched hydration). Key Massages: LD are not beneficial for AKI treatment if kidney-related endpoints are considered. In certain situations, AKI prevention with LD can be associated with favorable outcomes as long as euvolemia is maintained. LD can help to identify AKI subjects at a higher risk of AKI progression, but the exact clinical consequences need to be determined.

Citing Articles

Loop diuretics inhibit kynurenic acid production and kynurenine aminotransferases activity in rat kidneys.

Zakrocka I, Targowska-Duda K, Kocki T, Turski W, Urbanska E, Zaluska W Pharmacol Rep. 2024; 76(6):1415-1428.

PMID: 39261392 PMC: 11582277. DOI: 10.1007/s43440-024-00648-8.


Sildenafil and furosemide nanoparticles as a novel pharmacological treatment for acute renal failure in rats.

Sabra M, Allam E, Hassanein K Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7865-7879.

PMID: 38748227 PMC: 11449963. DOI: 10.1007/s00210-024-03128-1.


Beta 2-microglobulin is an independent risk marker of acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.

Zhao M, Liu J, Zhuang H, Qiu Y, He Z, Lin J J Nephrol. 2024; 37(5):1317-1325.

PMID: 38735000 PMC: 11405466. DOI: 10.1007/s40620-024-01949-0.


Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.

Lopes A, Lourenco O, Morgado S, Gaspar A, Freire I, Eusebio I Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675382 PMC: 11053518. DOI: 10.3390/ph17040420.


APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure.

Maiwall R, Singh S, Angeli P, Moreau R, Krag A, Singh V Hepatol Int. 2024; 18(3):833-869.

PMID: 38578541 DOI: 10.1007/s12072-024-10650-0.